Literature DB >> 17577820

Improved detection of Pneumocystis jirovecii infection in a tertiary care reference hospital in India.

Rashmi Gupta1, Bijay Ranjan Mirdha, Randeep Guleria, Anant Mohan, Sanjay Kumar Agarwal, Lalit Kumar, Susheel Kumar Kabra, Jyotish Chandra Samantaray.   

Abstract

We prospectively examined 143 clinical samples from 115 patients including both HIV infected (n=53) and HIV uninfected immunocompromized (n=62) patients, with lung infiltrates and with clinical features suggestive of Pneumocystis carinii pneumonia/ PneumoCystis Pneumonia (PcP), using both microscopic techniques as well as PCR assay. Clinical samples in the present study consisted of bronchoalveolar lavage (BAL), tracheal aspirate (TA), nasopharyngeal aspirate (NPA), sputum and gastric aspirate (GA). Another group of 21 individuals with other respiratory diseases not compatible with PcP served as control during the study period of 15 months. Overall, P. jirovecii positivity rate by PCR was 12.17% (14/115 patients) compared to 3.4% (4/115) by microscopy. None of the specimens in the control group was positive by any of the techniques used. All PCR negative patients including cases and controls showed no evidence of PcP. After resolution of the discrepant results upon review of the clinical data, the sensitivity and specificity were 100% and 99%, respectively, for PCR and 30.7% and 100%, respectively, for microscopy by GMS staining. Thus, our data support the significance of PCR assay for confirming and improving the diagnosis of PcP in high-risk patients.

Entities:  

Mesh:

Year:  2007        PMID: 17577820     DOI: 10.1080/00365540601131976

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  5 in total

Review 1.  Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches.

Authors:  Marjorie Bateman; Rita Oladele; Jay K Kolls
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

2.  Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay.

Authors:  Philippe M Hauser; Jacques Bille; Cornelia Lass-Flörl; Christian Geltner; Marta Feldmesser; Michael Levi; Hitesh Patel; Victoria Muggia; Barbara Alexander; Martin Hughes; Sarah A Follett; Xiaohui Cui; Flora Leung; Gillian Morgan; Adrian Moody; David S Perlin; David W Denning
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

Review 3.  Pneumocystis jirovecii pneumonia in developing countries.

Authors:  Y de Armas Rodríguez; G Wissmann; A L Müller; M A Pederiva; M C Brum; R L Brackmann; V Capó de Paz; E J Calderón
Journal:  Parasite       Date:  2011-08       Impact factor: 3.000

4.  Clinical characteristics and prognosis of patients with Pneumocystis jirovecii pneumonia without a compromised illness.

Authors:  Tae-Ok Kim; Jae-Kyeong Lee; Yong-Soo Kwon; Yu-Il Kim; Sung-Chul Lim; Min-Seok Kim; Bo Gun Kho; Cheol-Kyu Park; In-Jae Oh; Young-Chul Kim; Ha Young Park; Hong-Joon Shin
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

5.  Histoplasma capsulatum and Pneumocystis spp. co-infection in wild bats from Argentina, French Guyana, and Mexico.

Authors:  Antonio E González-González; Cécile M Aliouat-Denis; José A Ramírez-Bárcenas; Christine Demanche; Muriel Pottier; Laura E Carreto-Binaghi; Haroon Akbar; Sandra Derouiche; Magalie Chabé; El Moukhtar Aliouat; Eduardo Dei-Cas; Maria Lucia Taylor
Journal:  BMC Microbiol       Date:  2014-02-05       Impact factor: 3.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.